[go: up one dir, main page]

WO2009053895A3 - Quinoline urotensin-ii receptor antagonists - Google Patents

Quinoline urotensin-ii receptor antagonists Download PDF

Info

Publication number
WO2009053895A3
WO2009053895A3 PCT/IB2008/054311 IB2008054311W WO2009053895A3 WO 2009053895 A3 WO2009053895 A3 WO 2009053895A3 IB 2008054311 W IB2008054311 W IB 2008054311W WO 2009053895 A3 WO2009053895 A3 WO 2009053895A3
Authority
WO
WIPO (PCT)
Prior art keywords
urotensin
quinoline
receptor antagonists
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/054311
Other languages
French (fr)
Other versions
WO2009053895A2 (en
Inventor
Raymond J Kessler
Chengde Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of WO2009053895A2 publication Critical patent/WO2009053895A2/en
Publication of WO2009053895A3 publication Critical patent/WO2009053895A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are compounds that are modulators of urotensin-II receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of urotensin-II receptor activity.
PCT/IB2008/054311 2007-10-25 2008-10-20 Quinoline urotensin-ii receptor antagonists Ceased WO2009053895A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44407P 2007-10-25 2007-10-25
US61/000,444 2007-10-25

Publications (2)

Publication Number Publication Date
WO2009053895A2 WO2009053895A2 (en) 2009-04-30
WO2009053895A3 true WO2009053895A3 (en) 2009-06-11

Family

ID=40481934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/054311 Ceased WO2009053895A2 (en) 2007-10-25 2008-10-20 Quinoline urotensin-ii receptor antagonists

Country Status (1)

Country Link
WO (1) WO2009053895A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054850A1 (en) * 2003-02-28 2005-03-10 Chengde Wu Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054850A1 (en) * 2003-02-28 2005-03-10 Chengde Wu Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

Also Published As

Publication number Publication date
WO2009053895A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MY173616A (en) Compositions and methods for lowering triglycerides
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2010129816A3 (en) Heterocyclic compounds and uses thereof
IN2012DN01961A (en)
WO2010021693A3 (en) Mif modulators
MX2010002028A (en) Methods and compositions for modulating t cells.
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
EA201001329A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
UA98629C2 (en) Compounds and methods for kinase modulation
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2009089260A3 (en) Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EA201001332A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
WO2010034015A3 (en) Modulating the alternative complement pathway
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2011081928A3 (en) Compositions and methods for altering cocaine esterase activity
WO2009134962A3 (en) Claudin-4 binding peptides, compositions and methods of use
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841313

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17.08.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08841313

Country of ref document: EP

Kind code of ref document: A2